Oncotarget

Research Papers:

Efficacy and safety of angiogenesis inhibitors in small-cell lung cancer

Heng Lin, Lina Li, Shuimei Luo, Sijing Zhou, Ruifen Shen, Haitao Yang, Huijuan Chen and Xianhe Xie _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:1141-1155. https://doi.org/10.18632/oncotarget.13588

Metrics: PDF 2569 views  |   HTML 2084 views  |   ?  


Abstract

Heng Lin1,2,*, Lina Li1,*, Shuimei Luo1, Sijing Zhou1, Ruifen Shen1, Haitao Yang1, Huijuan Chen1, Xianhe Xie1

1Department of Chemotherapy, The First Affiliated Hospital, Fujian Medical University, Fuzhou, Fujian, China

2Department of Oncology, Fuzhou Pulmonary Hospital, Fuzhou, Fujian, China

*These authors have contributed equally to this work

Correspondence to:

Xianhe Xie, email: [email protected]

Keywords: angiogenesis inhibitors, chemotherapy, targeted therapy, small-cell lung cancer, meta-analysis

Received: July 02, 2016    Accepted: November 09, 2016    Published: November 25, 2016

ABSTRACT

Objective: The purpose of this study was to investigate the efficacy and safety of angiogenesis inhibitors for small-cell lung cancer (SCLC).

Methods: Totally, 16 controlled trials (1898 cases) involving angiogenesis inhibitors plus chemotherapy (ACT group) versus chemotherapy alone group (CT group) were identified from PubMed, EMBASE, Cochrane Library and Wanfang Data before March 2016.

Results: Compared with CT group, ACT group obtained a significant benefit on objective response rate (ORR) (RR = 1.34; 95% CI = 1.19-1.51; P < 0.00001) and a trend of prolonging progression-free survival (PFS) (HR = 0.86; 95% CI = 0.73-1.01; P = 0.07) without improving overall survival (OS) (HR = 1.05; 95% CI = 0.94-1.17; P = 0.36). Remarkably, subgroup analysis showed that the antibodies targeting VEGF significantly prolonged PFS (HR = 0.76; 95% CI = 0.64-0.90; P = 0.001). With regard to toxicity, there was no significant difference in severe adverse events (AEs, Grade≥3) between two groups except that gastrointestinal symptom, hypertension, metabolic disorders, neurology and pain were higher in ACT group.

Conclusion: Compared with chemotherapy alone, antibodies targeting VEGF plus chemotherapy significantly improved ORR and prolonged PFS with an acceptable toxicity profile for patients with SCLC. Therefore, angiogenesis inhibitors, especially antibodies targeting VEGF, combining with chemotherapy may be a potential promising strategy in managing SCLC.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 13588